| Autor: |
Zhang Sijia, Xiao Yu, Chen Leichong, Li Zhenyu, Zong Yan, Zhu Kuikui, Meng Rui |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Open Life Sciences, Vol 17, Iss 1, Pp 577-585 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2391-5412 |
| DOI: |
10.1515/biol-2022-0062 |
| Popis: |
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and highly aggressive cancer with a very poor prognosis. The proper treatment decision and possible prognosis outcome for advanced LCNEC is always an enormous challenge due to its scarcity. Here, we presented a 59-year-old male patient with advanced LCNEC with a non-neuroendocrine immunophenotype who received endostar plus pembrolizumab combined with a platinum-based dual chemotherapy regime as a first-line treatment. At present, the patient’s condition is well controlled by medication only and has a progression-free survival of more than 2 years. Adverse effects recorded for this patient during treatment courses include nausea, vomiting, II–III quality bone marrow toxicity, and PD-1 blockage-related hypothyroidism. This case report discussed the feasibility of immunotherapy, anti-angiogenesis agents, and chemotherapy as a first-line therapy in advanced LCNEC. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
